Diet and Lifestyle in a Prospective Study of Bladder Cancer Survivors
膀胱癌幸存者的饮食和生活方式前瞻性研究
基本信息
- 批准号:9059032
- 负责人:
- 金额:$ 98.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-07-02 至 2019-05-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAddressAdverse effectsAgeAnimal ModelArsenicBiological AvailabilityBladderCaliforniaCalmette-Guerin BacillusCancer PatientCancer PrognosisCancer SurvivorCancer cell lineCaringCessation of lifeChemopreventive AgentClinical ManagementCohort StudiesCystoscopyDatabasesDiagnosisDietDiet ModificationDietary IsothiocyanateDiseaseDisease ProgressionEnhancersEnzymesEpidemiologic StudiesEpithelialEpitheliumEthnic OriginFutureGenesGeneticGenetic PolymorphismGoalsHealthHealthcareHumanImmune systemImmunotherapeutic agentIn VitroIncidenceIndividualIntakeIntervention TrialIsothiocyanatesLamina PropriaLife StyleLong-Term EffectsMalignant NeoplasmsMalignant neoplasm of urinary bladderMeasuresMedicalMetabolic PathwayMetabolismMitomycinsModalityMuscleNQO1 geneNewly DiagnosedOccupationsOlder PopulationOutcomeOxidoreductasePatientsPhasePhytochemicalPlayPreventionProspective StudiesPublic HealthQuality of lifeQuestionnairesQuinonesRaceRecurrenceRequest for ApplicationsRetrospective StudiesRiskRoleSmokingStagingTherapeutic AgentsTherapeutic EffectTimeTreatment EfficacyUnited StatesUrineVegetablesWorkcancer diagnosiscancer recurrencecancer riskcancer survivalchemotherapeutic agentclinical carecohortcookingcostcruciferous vegetabledrug sensitivitygenetic profilinggenetic varianthigh riskimmune functionimprovedin vivointravesicallifestyle factorsoutcome forecastpreventprogramsprospectivesextumortumor progressionurinary
项目摘要
DESCRIPTION (provided by applicant): Bladder cancer is one of the top ten most common cancers in the U.S., contributing to over 60,000 new cases and 10,000 deaths annually. The majority of cases (70-80%) are diagnosed at early stage (termed "non-muscle invasive"), yet the cancer typically recurs (50-80%), with a subset further progressing to muscle- invasive disease with poor survival. Due to this markedly high recurrence and progression, patients are followed intensively by cystoscopy with repeat transurethral manipulation, making bladder cancer one of the most costly diseases. Cruciferous vegetable intake has been associated with reduced risk of primary bladder cancer and improved survival, which might be partly attributable to their unique phytochemical isothiocyanates (ITCs). Dietary ITCs are promising chemopreventive agents with multi-faceted anti-cancer mechanisms. Our prior in vitro, in vivo, and epidemiologic studies strongly support dietary ITCs and ITC-rich cruciferous vegetables playing a key role in preventing bladder cancer recurrence and progression and improving prognosis. Above all, via metabolic pathways in humans, orally ingested ITCs are rapidly delivered to the bladder and concentrated in the urine, rendering bladder cancer the best target for their anti-cancer activities. This application requests to conduct a new prospective cohort study of 1,811 newly diagnosed non- muscle invasive bladder cancer patients in the Kaiser Permanente Northern California (KPNC) and Southern California (KPSC) Medical Care Programs. Our goal is to comprehensively examine the role of cruciferous vegetable intake, in conjunction with genetic polymorphisms related to ITC metabolism, in potentially reducing disease recurrence and progression, and increasing the efficacy of intravesical treatment. We propose to investigate: 1) the associations between cruciferous vegetable intake and bladder cancer recurrence and progression; 2) the modifying effect of polymorphisms of ITC-metabolizing genes on the associations between cruciferous vegetable intake and bladder cancer recurrence and progression; and 3) the effects of the interactions between cruciferous vegetable intake and therapeutic agents on bladder cancer recurrence and progression. Furthermore, we propose to establish the largest prospective cohort of non-muscle invasive bladder cancer patients with longitudinal questionnaire data and banked biospecimens for further future research of bladder cancer outcomes including survival and quality of life. Bladder cancer is an extremely understudied disease considering its disproportionate high incidence and recurrence, high cost of clinical management, and significant impact on quality of life. The proposed study within one of the largest U.S. integrated health care settings will be the first to investigate the role of dit in recurrence and progression of the disease, with genetic profiles taken into consideration to identify those who will benefit most. Considering the wide availability of cruciferous vegetables in the U.S., this study could have an immediate impact on bladder cancer prognosis.
描述(由申请人提供):膀胱癌是美国十大最常见的癌症之一,每年造成60,000多例新病例和10,000例死亡。大多数病例(70-80%)在早期诊断出(称为“非肌肉侵入性”),但癌症通常会复发(50-80%),子集进一步发展为肌肉侵入性疾病,生存率较差。由于这种明显的复发和进展,患者紧随其后,进行膀胱镜检查,并反复进行尿道操纵,使膀胱癌成为最昂贵的疾病之一。十字花科蔬菜摄入量与降低原发性膀胱癌的风险和改善生存率有关,这可能部分归因于其独特的植物化学异硫氰酸盐(ITC)。饮食ITC是具有多方面抗癌机制的有希望的化学预防剂。我们先前的体外,体内和流行病学研究强烈支持饮食中的ITC和富含ITC的十字花科蔬菜在防止膀胱癌复发,进展和改善预后方面发挥了关键作用。最重要的是,通过人类的代谢途径,口服摄入的ITC迅速输送到膀胱并集中在尿液中,使膀胱癌成为其抗癌活性的最佳靶标。 该申请要求对1,811个新诊断的非肌肉浸润性膀胱癌患者进行新的前瞻性队列研究,该研究在加利福尼亚州北加州北加州(KPNC)和南加州(KPSC)医疗计划中进行。我们的目标是全面研究十字花科蔬菜摄入的作用,以及与ITC代谢相关的遗传多态性,在潜在地减少疾病复发和进展以及提高静脉治疗的功效方面的作用。我们建议研究:1)十字花科蔬菜摄入与膀胱癌复发和进展之间的关联; 2)ITC-代谢基因多态性对十字花科蔬菜摄入与膀胱癌复发和进展之间关联的修改作用; 3)十字花科蔬菜摄入与治疗剂之间相互作用对膀胱癌复发和进展的影响。此外,我们建议建立具有纵向问卷数据和存储生物测量的非肌肉侵入性膀胱癌患者的最大前瞻性队列,以进一步研究膀胱癌结果,包括生存和生活质量。 考虑到其不成比例的高发病率和复发,临床管理的高成本以及对生活质量的重大影响,膀胱癌是一种严格研究的疾病。在美国最大的综合医疗保健环境之一中提出的研究将是第一个研究DIT在疾病复发和进展中的作用的研究,并考虑了遗传特征以识别那些将受益最大的人。考虑到美国十字花科蔬菜的广泛可用性,这项研究可能会对膀胱癌的预后产生直接影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
LAWRENCE H KUSHI其他文献
LAWRENCE H KUSHI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('LAWRENCE H KUSHI', 18)}}的其他基金
Diet and Lifestyle in a Prospective Study of Bladder Cancer Survivors
膀胱癌幸存者的饮食和生活方式前瞻性研究
- 批准号:
8695166 - 财政年份:2014
- 资助金额:
$ 98.7万 - 项目类别:
Diet and Lifestyle in a Prospective Study of Bladder Cancer Survivors
膀胱癌幸存者的饮食和生活方式前瞻性研究
- 批准号:
9282392 - 财政年份:2014
- 资助金额:
$ 98.7万 - 项目类别:
CRN4: Cancer Research Resources & Collaboration in Integrated Health Care Systems
CRN4:癌症研究资源
- 批准号:
8920517 - 财政年份:2012
- 资助金额:
$ 98.7万 - 项目类别:
CRN4: Cancer Research Resources & Collaboration in Integrated Health Care Systems
CRN4:癌症研究资源
- 批准号:
9120967 - 财政年份:2012
- 资助金额:
$ 98.7万 - 项目类别:
CRN4: Cancer Research Resources & Collaboration in Integrated Health Care Systems
CRN4:癌症研究资源
- 批准号:
8733630 - 财政年份:2012
- 资助金额:
$ 98.7万 - 项目类别:
CRN4: Cancer Research Resources & Collaboration in Integrated Health Care Systems
CRN4:癌症研究资源
- 批准号:
8550798 - 财政年份:2012
- 资助金额:
$ 98.7万 - 项目类别:
CRN4: Cancer Research Resources & Collaboration in Integrated Health Care Systems
CRN4:癌症研究资源
- 批准号:
8401712 - 财政年份:2012
- 资助金额:
$ 98.7万 - 项目类别:
相似国自然基金
时空序列驱动的神经形态视觉目标识别算法研究
- 批准号:61906126
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
本体驱动的地址数据空间语义建模与地址匹配方法
- 批准号:41901325
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
- 批准号:61802133
- 批准年份:2018
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
- 批准号:61872252
- 批准年份:2018
- 资助金额:64.0 万元
- 项目类别:面上项目
针对内存攻击对象的内存安全防御技术研究
- 批准号:61802432
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Reproductive history and later-life brain health: The Bogalusa Heart Study
生殖史和晚年大脑健康:Bogalusa 心脏研究
- 批准号:
10736169 - 财政年份:2023
- 资助金额:
$ 98.7万 - 项目类别:
Mitoquinone/mitoquinol mesylate as oral and safe Postexposure Prophylaxis for Covid-19
米托醌/甲磺酸米托喹诺作为 Covid-19 的口服且安全的暴露后预防
- 批准号:
10727092 - 财政年份:2023
- 资助金额:
$ 98.7万 - 项目类别:
Gabapentinoid/opioid mixtures: abuse and toxicity
加巴喷丁/阿片类混合物:滥用和毒性
- 批准号:
10639396 - 财政年份:2023
- 资助金额:
$ 98.7万 - 项目类别:
Physical Frailty and Symptom Monitoring and Management Behaviors in Heart Failure (PRISM-HF)
心力衰竭的身体虚弱和症状监测和管理行为 (PRISM-HF)
- 批准号:
10740609 - 财政年份:2023
- 资助金额:
$ 98.7万 - 项目类别:
Class II Human Leukocyte Antigen biologics for antibody-mediated graft rejection.
用于抗体介导的移植物排斥反应的 II 类人类白细胞抗原生物制剂。
- 批准号:
10598931 - 财政年份:2023
- 资助金额:
$ 98.7万 - 项目类别: